Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study

Yamashita, Tatsuya; Arai, Kuniaki; Sakai, Akito; Mizukoshi, Eishiro; Sakai, Yoshio; Kagaya, Takashi; Nakamoto, Yasunari; Honda, Masao; Wada, Takashi; Yokoyama, Hitoshi

doi:10.1016/j.hepres.2006.07.013

Cited by 19 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have reported the use of DFPP for HCV treatment [4][5][6]. Fujiwara et al [4] demonstrated that DFPP plus IFN combination therapy produced a considerable reduction in the viral load during the early stage of treatment and yielded a high SVR rate.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

et al. 2014

View full text Add to dashboard Cite

A 66-year-old, hepatitis C virus (HCV)-positive woman was admitted to our hospital with oliguria, systemic edema, and rapid deterioration of renal function. Laboratory examination showed increased serum creatinine and decreased serum albumin levels, complement activity, and cryoglobulin positivity. The HCV RNA genotype was found to be 1b, and the viral load was high. Kidney biopsy examination showed type I membranoproliferative glomerulonephritis with capillary deposition of IgM and C3, indicating HCV-related glomerulonephritis. After hospitalization, hemodialysis was immediately required because of uremia and oliguria. Her renal function did not improve despite corticosteroid therapy. To treat the increasing HCV load, virus removal and eradication by double-filtration plasmapheresis therapy without interferon was performed, since the patient was allergic to interferon therapy. This treatment improved renal function and allowed the withdrawal from hemodialysis. This report presents a case of successful VRAD without interferon therapy in a patient with HCV-related glomerulonephritis and acute kidney injury that required hemodialysis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…VRAD therapy was administered as described previously [4][5][6]. A Plasmaflo TM OP-08W (Asahi Kasei Medical) and an Evaflux TM 5A20 (Asahi Kasei Medical) were used as the plasma separator (first filter) and plasma fractionator (second filter), respectively.…”

Section: Case Reportmentioning

confidence: 99%

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

et al. 2014

View full text Add to dashboard Cite

show abstract

“…DFPP replacement fluid was not required. DFPP was performed a total of five times over a period of two weeks, but never on more than two consecutive days in order to prevent the blood fibrinogen levels decreasing to <100 mg/dl (9).…”

Section: Methodsmentioning

confidence: 99%

Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin

Ishikawa

Abe

Kojima

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to determine predictors of a sustained virological response (SVR) with a regimen of double filtration plasmapheresis (DFPP) combined with interferon-β plus ribavirin (IFN-β/RBV) induction therapy prior to pegylated (PEG-IFN/RBV) standard of care (SOC) therapy for patients with chronic hepatitis C who had experienced SOC treatment failure. Predictors of a SVR were analyzed in chronic hepatitis C patients with genotype 1b hepatitis C virus (HCV), who had a high viral load. The patients had been unresponsive to previous IFN therapy and underwent induction therapy with IFN-β/RBV plus DFPP, which was performed five times during the same period, followed by PEG-IFN/RBV. In total, 10 patients received the combination DFPP plus IFN-β/RBV induction therapy prior to PEG-IFN/RBV therapy for the treatment of chronic hepatitis C. Two weeks after treatment initiation, a decrease in the HCV RNA levels of ≥2 log IU/ml occurred in 9/10 patients (90%), while a decrease of ≥4 log IU/ml was observed in 4/10 patients (40%). The HCV RNA levels at week 2 after treatment initiation in the SVR and non-SVR patients decreased by 5.0±0.8 and 2.9±1.1 log IU/ml, respectively. Despite no response to previous IFN therapy, three of the 10 patients (30%) experienced a SVR. The results indicated that a rapid virological response ensued following IFN-β/RBV induction and DFPP supplementary therapy. Although the level of interleukin-28B is an important predictor of a SVR, a decrease in the HCV RNA volume of ≥4 log IU/ml at week 2 after the initial treatment is also an important predictor. Therefore, rapid virological reduction using DFPP, in addition to IFN-β/RBV induction therapy, is an important predictor of a SVR.

show abstract

“…Treatment by plasma aphaeresis has been used effectively on patients afflicted with hepatitis C infection [11]- [14], and cancer [15]. In plasma aphaeresis, the virus particles in the larger components of the plasma are removed from a patient, after which the small molecular components of plasma and cellular components of the blood are returned to the patient.…”

Section: Introductionmentioning

confidence: 99%

Investigating Combined Drug and Plasma Apheresis Therapy of HIV Infection by Double Compartment Cellular Automata Simulation

Moonchai¹,

Lenbury²

2016

IJCTE

View full text Add to dashboard Cite

Abstract-It has become widely acknowledged that potent combination drug therapy of patients infected with Human Immunodeficiency Virus can significantly prolong life, but exerts detrimental effect on a patient's quality of life. Lymph nodes and lymphatic tissue are busy sites of immunological activity. Germs are brought there by the cells of the immune system to be broken down and analyzed. However, clinics commonly used blood tests for viral load therein to assess the effect of drug therapy. We are therefore of the opinion that most cellular automata models in the past that only considered viral proliferation in the lymph node cannot give a sufficiently accurate picture of the dynamics of HIV infection, especially when the impact of treatments that combine both drugs and plasma apheresis are in question. We thus present a two-compartment cellular automata (CA) model, which simulates the dynamics of HIV infection in both the lymph node and blood compartments when drugs and plasma apheresis are applied simultaneously. It is found that the combined usage of these two types of therapy yields more favorable outcome than the sole use of plasma apheresis.

show abstract

Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study

Cited by 19 publications

References 31 publications

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin

Investigating Combined Drug and Plasma Apheresis Therapy of HIV Infection by Double Compartment Cellular Automata Simulation

Contact Info

Product

Resources

About